Updates are available Correction dated 2019-05-14

Article History

First Online: 8 September 2018

Change Date: 14 May 2019

Change Type: Correction

Change Date: 14 May 2019

Change Type: Correction

Change Details: Correction to Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.

Change Details: Correction to Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.

Compliance with Ethical Standards

:

: Mark Bounthavong and David L. Veenstra report consulting relationships with Relypsa, Inc., a Vifor Pharma Group Company. Javed Butler reports consultancy/advisory board fees from Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, Inc., a Vifor Pharma Group Company, Stealth Peptide, SC Pharma, Vifor, and ZS Pharma; other research support and research grants from European Union and the National Institutes of Health; and speaker/honoraria from Novartis and Janssen. Chantal M. Dolan and Kathryn A. Fisher are employees of CMD Consulting, and report consulting relationships with Genentech Inc., Gilead Sciences, Halozyme Therapeutics, Iconic Therapeutics, Semnur Pharmaceuticals and Relypsa, Inc., a Vifor Pharma Group Company. Jeffrey A. Dunn reports consultancy/advisory board fees from Relypsa, Inc., a Vifor Pharma Group Company. Nina Oestreicher reports previous employment by Relypsa, Inc., a Vifor Pharma Group Company at the time of the study. Bertram Pitt reports serving as a consultant to Sanofi, Relypsa, Merck, Bayer, AstraZeneca, scPharmaceuticals, Tricida, KBP Biosciences, Stealth Peptides, Sarfez, and AuraSense; stock options in scPharmaceuticals, Tricida, KBP Biosciences, Sarfez, and AuraSense; serving on data safety monitoring committees for and receiving personal fees from Johnson & Johnson; and, in addition, he has a pending patent EFS ID 14916043, application number licensed to the University of Michigan School of Medicine. Paul J. Hauptman reports consultant/advisory board fees, research grants, and speaker/honoraria from Relypsa, Inc., a Vifor Pharma Group Company.

: Funded by Relypsa, Inc., a Vifor Pharma Group Company.

: The following describes the contributions each author made to this work: conception and design—all authors; data collection and analysis—MB and KAF; manuscript drafting—MB; revisions and approval of final manuscript—all authors.

: All data analyzed or generated during this study are included in this published article (and its online supplementary information files). Any additional information about assumptions or analytic techniques in the current study are available from the corresponding author on reasonable request.